Spironolactone reduces heart failure hospitalizations, but not mortality, study says. ScienceDaily. Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2013 / 11 / 131118132925.htm.

Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2014; 370 (15): 1383 DOI: 10.1056/NEJMoa1313731; Cite This Page: MLA; APA; Chicago; ...

Inappropriate use of spironolactone in heart failure. Lisa Nainggolan. November 23, 2000. Thu, 23 Nov 2000 17:25:38 ...

At the end of the study, 206 out of 1722 patients on spironolactone (12 percent) had been hospitalized for heart failure, compared to 245 of 1723 patients (14 percent) given placebo.

Although the mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone (Inspra, Pfizer) have been shown to be beneficial in patients with heart failure (HF) with reduced ejection ...

Research indicates that spironolactone may reduce rehospitalizations and 30-day mortality in patients with acute heart failure (AHF).

Jan. 31, 2003 — The Randomized Spironolactone Evaluation Study (RALES) demonstrated the usefulness of spironolactone in low doses for the management of severe heart failure. However, an ...

Spironolactone, a blood pressure medication, may help reduce risk of new heart failure American Heart Association Scientific Sessions 2024, Abstract 4168086 ...

Spironolactone is a medicine that is really old. It's been around for decades. And it is classified pharmacologically as a diuretic, even though its diuretic effect at the doses we use in heart ...

Research Highlights: The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not significantly impact the rate of death, new heart ...

Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone ...

A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, to be presented at the American Heart Association ...